Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2018-001292-21-FR (EUCTR)	27/07/2018	05/06/2018	Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years	Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years	Secondary Progressive Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10063400;Term: Secondary progressive multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: AVONEX Product Name: BETAFERON Product Code: L03 AB 08 Product Name: EXTAVIA Product Name: REBIF Product Name: PLEDIGRY Product Name: COPAXONE Product Name: AUBAGIO Product Name: TECFIDERA Product Name: GILENYA Product Name: TYSABRI Product Name: IMUREL Product Name: NOVATREX Product Name: CELLCEPT Product Name: ENDOXAN	CHU de Rennes	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	250	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	France
2	NCT00618527 (ClinicalTrials.gov)	August 2006	6/2/2008	Combination Therapy Using Cellcept and Rebif in RRMS	Combination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple Sclerosis	Multiple Sclerosis	Drug: mycophenolate mofetil (Cellcept);Drug: human interferon beta 1a (Rebif)	Aaron Boster	EMD Serono;Pfizer	Completed	18 Years	65 Years	Both	31	Phase 0	United States
3	NCT00324506 (ClinicalTrials.gov)	May 2006	9/5/2006	Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis	A Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple Sclerosis	Multiple Sclerosis	Drug: Mycophenolate Mofetil (CellCept)	University of Texas Southwestern Medical Center	Aspreva Pharmaceuticals	Completed	18 Years	55 Years	Both	43	Phase 2	United States
4	NCT00223301 (ClinicalTrials.gov)	July 2004	19/9/2005	Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis	A One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple Sclerosis	Multiple Sclerosis	Drug: Mycophenolate Mofetil (cellcept)	University of Texas Southwestern Medical Center	Roche Pharma AG;Biogen Idec	Completed	21 Years	45 Years	Both	24	Phase 2/Phase 3	United States